Mainstream Media Claim: A nasal CBD nanomedicine could rapidly deliver cannabidiol to the brain and transform treatment for Dravet and Lennox Gastaut syndromes.

Primary Journal Data: The article is a narrative translational review of studies identified through PubMed, Scopus, Web of Science, and Google Scholar up to March 2026. It reports preclinical evidence that intranasal nanostructured lipid carrier CBD can increase brain exposure, improve brain-to-plasma ratios, and show anticonvulsant effects in animal seizure models, including pentylenetetrazol-induced convulsions. It reports no completed pediatric DS or LGS clinical trial, no human efficacy endpoint, and no validated clinical dosing regimen.

Dr. Caplan’s Clinical Verdict: Promising formulation science, but not a patient-ready epilepsy therapy. The correct clinical stance is curiosity with guardrails: continue evidence-based seizure care, consider prescription cannabidiol when appropriate, and wait for pediatric pharmacokinetic, safety, and efficacy trials before using intranasal NLC-CBD clinically.

Study Overview: Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are severe developmental epileptic encephalopathies that appear in early childhood, are unresponsive to medications, and have a dismal neurodevelopmental prognosis. Most patients do not respond well to polytherapy, and the need to fulfill this gap in clinical practice is urgent. Cannabidiol (CBD) has proven to be an effective adjunct drug, but oral preparations have low bioavailability, slow onset and systemic adverse effects. Nanostructured lipid carriers (NLCs) are an innovative therapeutic technology that can deliver CBD directly to the brain via the nose, enhance brain targeting, achieve faster onset, and minimize systemic exposure, which could be a valuable solution to current deficiencies in treatment.Intranasal NLC-CBD has preclinical evidence of increasing brain CBD levels, facilitating anticonvulsant action, and protecting against seizures in established animal models, like pentylenetetrazol-induced convulsions. NLC-based preparations have increased brain-to-plasma ratios and longer central exposure at lower doses in comparison to free or orally administered CBD. Despite these promising findings, there are still translational gaps to be addressed, such as insufficient safety data in the long term, disease-specific DS/LGS genetic models, inconsistencies in the pediatric nasal physiology, and conventional clinical dosing paradigms.Literature for this review was identified through searches of PubMed, Scopus, Web of Science, and Google Scholar, covering studies published up to March 2026 on CBD, NLC, intranasal drug delivery, DS, and LGS.There is a dire need to carry out properly designed clinical trials that would demonstrate the safety, pharmacokinetics (PK) and efficacy of intranasal NLC-CBD in DS and LGS. The first pediatric clinical trials, adaptive trial models and regulatory harmonization are necessary to convert this noble nanomedicine approach into a clinical therapy. Dravet syndrome (DS) and Lennox-Gastaut syndrome (LGS) are rare and severe forms of epilepsy which often start in childhood. A significant number of patients fail to respond to several antiseizure drugs, and have recurrent seizures. Cannabidiol (CBD) is a chemical found in the cannabis plant that is effective in reducing seizures, but there are some limitations in oral CBD products, including slow absorption and inconsistent efficacy and the possibility for drug interaction. In this review, a novel delivery system of delivering CBD to the brain via a nose spray containing nanostructured lipid carriers (NLCs) is investigated. The use of these tiny lipid-based particles can aid in the delivery of CBD to the brain more rapidly and effectively, avoiding the digestion process and lowering first-pass metabolism. Consequently, intranasal NLC-CBD is likely to have a quicker onset of effect, better brain penetration, and reduced doses. This review provides a summary of existing preclinical evidence, as well as safety and regulatory considerations and outlines the possible clinical development options for this technology. It also underscores some of the future possibilities, such as the application of artificial intelligence (AI), novel clinical trial designs, and combination therapies. While additional clinical trials are necessary, intranasal NLC-CBD is a promising approach for better seizure control, quality of life and treatment ease for DS and LGS patients and their caregivers.

Primary Source & Scope: Published in Therapeutic delivery (2026Sep17) conducted by Yashika, Sachin Yadav, Anish Arora, Nisha Bharti et al.. Primary Source Link | Primary Record: DOI: 10.1080/20415990.2026.2731738 | PMID: 42751849

Clinical research into Nanostructured lipid carriers for intranasal canna is progressing through rigorously documented peer-reviewed cohorts.

Evaluating primary evidence enables clinicians to tailor care plans while respecting therapeutic boundaries.

The clinically attractive idea here is not simply cannabidiol, since prescription oral CBD already has a role in Dravet syndrome and Lennox Gastaut syndrome. The important proposal is route and formulation: a lipid nanocarrier administered through the nose may bypass part of gastrointestinal variability and first-pass metabolism, potentially producing more efficient central nervous system exposure. That could matter for children whose seizure burden remains high despite polytherapy, and for families navigating sedation, appetite changes, diarrhea, transaminase elevation, and antiseizure drug interactions.

But this paper does not let us prescribe around those problems yet. Animal seizure models, improved brain-to-plasma ratios, and longer central exposure are mechanistic signals, not pediatric outcomes. The major unanswered questions are practical and clinical: nasal tolerability in young children, reproducible dosing during congestion or crying, chronic mucosal safety, developmental pharmacokinetics, device performance, caregiver technique, and whether seizure frequency, drop attacks, status epilepticus risk, sleep, cognition, and quality of life actually improve.

Three Rules for Critical Reading